Literature DB >> 11162418

Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD.

M Cazzola1, S Centanni, C Regorda, F di Marco, F di Perna, P Carlucci, B Boveri, P Santus.   

Abstract

We studied 16 patients with stable COPD in a double blind, double dummy, placebo-controlled, within patient study to see if formoterol could be used as a rescue drug. We compared the of onset of bronchodilation obtained with formoterol 12 microg (metered dose corresponding to 9 microg delivered dose) and formoterol 24 microg (metered dose corresponding to 18 microg delivered dose), both delivered via Turbuhaler, with that of salbutamol 400 microg and salbutamol 800 microg delivered via pressurized metered-dose inhaler (pMDI). Patients inhaled single doses of placebo, formoterol and salbutamol on five separate days. FEV1 was measured in baseline condition and 3, 6, 9, 12, 15, 18, 21, 24, 30, 40, 50, and 60 min after inhalation of each treatment. We examined two separate criteria for deciding if a response was greater than that expected by a random variation of the measurement: (1) a rise in FEV1 of at least 15% from the baseline value; (2) an absolute increase in FEV1 of at least 200 ml. Formoterol 12 microg (15.2 min; 95% CI 9.5-21.0) and formoterol 24 microg (15.1 min; 95% CI 8.9-21.2) caused a rise in FEV1 of at least 15% from the baseline value almost rapidly as salbutamol 400 microg (13.6 min; 95% CI 7.1-20.1) and salbutamol 800 microg (14.5 min; 95% CI 7.1-21.9). No significant difference (P=0.982) in onset of action was seen between the four active treatments. According to Criterion 2, the mean time to 200 ml increase in FEV1 was 11.1 min (95% CI: 7.0-15.2) after salbutamol 400 microg, 13.0 min (95% CI: 7.9-18.1) after salbutamol 800 microg, 14.7 min (95% CI: 7.1-22.4) after formoterol 12 microg, and 12.7 min (95% CI: 7.4-18.0) after formoterol 24 microg. Again, there was no significant difference (P= 0.817) between the four active treatments. Formoterol Turbuhaler 12 microg and 24 microg caused bronchodilation as rapidly as salbutamol 400 microg and 800 microg given via pMDI.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11162418     DOI: 10.1006/pupt.2000.0267

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  7 in total

1.  Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose-response study.

Authors:  Christopher I Whale; Milind P Sovani; Kevin J Mortimer; Timothy W Harrison; Anne E Tattersfield
Journal:  Br J Clin Pharmacol       Date:  2008-04-03       Impact factor: 4.335

2.  Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial.

Authors:  Donald P Tashkin; Dennis E Doherty; Edward Kerwin; Carlos E Matiz-Bueno; Barbara Knorr; Tulin Shekar; Sibabrata Banerjee; Heribert Staudinger
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-02-03

3.  Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.

Authors:  Dennis E Doherty; Donald P Tashkin; Edward Kerwin; Barbara A Knorr; Tulin Shekar; Sibabrata Banerjee; Heribert Staudinger
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-02-03

Review 4.  Budesonide-formoterol (inhalation powder) in the treatment of COPD.

Authors:  Erkan Ceylan
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

5.  Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.

Authors:  Donald P Tashkin; Dennis E Doherty; Edward Kerwin; Carlos E Matiz-Bueno; Barbara Knorr; Tulin Shekar; Davis Gates; Heribert Staudinger
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-02-03

Review 6.  Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease.

Authors:  Maria Gabriella Matera; Alessandro Sanduzzi; Mario Cazzola
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-01-05

Review 7.  Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide.

Authors:  Marco Mantero; Dejan Radovanovic; Pierachille Santus; Francesco Blasi
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-07-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.